Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

NICE gives denosumab green light

By Lara Hutchins

NICE have given the go-ahead for denosumab - the first monoclonal antibody osteoporosis treatment – to be prescribed as an alternative to bisphosphonates for primary and secondary prevention of osteoporotic fractures in post-menopausal women.

Denosumab is given as a single 60mg/ml subcutaneous injection every six months and works by inhibiting osteoclast resorption.

The FREEDOM study measured the percentages of radio graphically detected spinal fractures at 36 months in patients receiving denosumab versus placebo, at 2.3% versus 7.2% respectively. Other findings support its benefit over placebo to prevent wrist and hip fractures.

NICE says post-menopausal women with osteoporosis and a T-score greater -2.5 who are bisphosphonate intolerant (or unable to follow the administration instructions) are eligible for denosumab if they meet one other criteria including maternal or paternal hip fracture and co-existing rheumatoid arthritis.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say